CymaBay -Seladelpar Phase 3 Enhance Study shows positive results

CymaBay -Seladelpar Phase 3 Enhance Study shows positive results

CymaBay -Seladelpar Phase 3 Enhance Study shows positive results

At AASLD 2020 virtual liver conference, Dr. Gideon Hirschfield presented promising Phase 3 results for Seladelpar a treatment for patients with PBC.  Positive outcomes included: 78% of those in the study achieved primary (composite) endpoint at 3 months, ALP normalization and improvement in pruritus.  

shares